NCT05998447 2025-12-16
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
Phase 2 Terminated
Clinical Trials
12 trialsNCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT03291899 2024-01-17
FBI-TRAC
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated
NCT04566133 2023-08-21
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03790111 2023-04-19
TELE-ABC
TerSera Therapeutics LLC
Phase 2 Terminated
NCT04784520 2023-02-06
A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Terminated
NCT01773785 2021-10-13
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT00868998 2016-05-23
GTX Regimen for Biliary Cancers
Columbia University
Phase 2 Terminated
NCT00881504 2014-10-20
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Georgetown University
Phase 2 Terminated
NCT01171755 2014-05-21
GetBil
Samsung Medical Center
Phase 2 Terminated
NCT01096745 2011-06-23
Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer
Gyeongsang National University Hospital
Phase 2 Terminated